Journal Logo

June 25th, 2003 - Volume 25 - Issue 12
pp: 4-73

Environmental Genome Project Yields New Data That May Trigger Clinical Advances

Eastman, Peggy

Oncology Times. 25(12):5-7, June 25th, 2003.

The EGP, which is characterizing genetic variations that confer susceptibility to environmental agents that can cause disease, has already yielded key information on a gene variation that will be useful in identifying men at increased risk for prostate cancer.

Oral Anabolic Steroid Effective for Cancer Cachexia

Laino, Charlene

Oncology Times. 25(12):15-16, June 25th, 2003.

Oxandrolone can help cancer patients with involuntary weight loss gain lean body mass, while improving quality of life and performance status, according to a preliminary prospective study, which suggests it also helps reverse the underlying pathology, improving metabolically active tissue compartments.

Cancer-Related Fungal Infections on the Rise, But New Drugs Transforming Treatment

Pfeiffer, Naomi

Oncology Times. 25(12):22,25-26, June 25th, 2003.

Researchers are excited by the new antifungals—both those recently approved and others still in clinical development—which are safer, have a different mechanism of action, and can be dosed less frequently due to a longer half life.

Multiple Myeloma: New Drug Update

Goodman, Alice

Oncology Times. 25(12):28-31, June 25th, 2003.

Biological discoveries are leading to new drugs for myeloma, along with new methods of managing bone disease. Novel agents like Revimid and bortezomib not only target the tumor, but also act in the bone marrow microenvironment, making it possible to overcome drug resistance.

Tips on Minimizing Drug-Drug Adverse Interactions

Fuerst, Mark L.

Oncology Times. 25(12):35, June 25th, 2003.

An explosion in the number and types of drugs and drug combinations has upped the potential for drug interactions. Cancer patients, in particular, are at risk. In addition, a large proportion are elderly, a population that has an inherently high chance for such problems.

Dr. Michael Friedman, After Serving at the NCI, FDA, and Pharmacia, Returns to Academia as CEO of City of Hope

Laino, Charlene

Oncology Times. 25(12):41-42, June 25th, 2003.

After serving at the NCI, FDA, & Pharmacia, he returns to academia as CEO of City of Hope. He talks here about his diverse experiences, what he has learned, and his plans for his new position.